

Tandem Pharmacist Conference at the 2022 Tandem Meetings | Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

April 23 – 24, 2022

Target Audience

This activity is intended for clinical pharmacists, residents, and nurses who specialize in or are training in blood and marrow transplantation (BMT).

Accredited Provider

This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.



Program Overview

The Tandem Pharmacists Conference is a 2-day session held annually in conjunction with the Tandem Meetings of ASTCT and CIBMTR. This conference features leaders of the pharmacy profession specializing in HCT and cellular therapy, along with their colleagues and experts from other medical disciplines, who provide perspective and an evidence-based approach to the emerging issues and clinical management of this complex patient population.

Overall Program Learning Objectives

- Discuss current clinical practice and challenges for pharmacists in the field of blood and marrow transplantation (BMT) and cellular therapy.
- Identify best practice strategies and clinical challenges related to infection prevention and management in CAR T-cell therapy patients, the role of bone health and vitamin D in HCT/CI patients, HCT for inherited bone marrow failures in the pediatric population, new drug therapies and updates in multiple myeloma, and COVID-19 vaccination and monoclonal therapy strategies in HCT/CI patients, and updated therapies for GVHD Prevention and Treatment
- Examine challenging patient cases related to Primary Graft Failure and HHV6
- Analyze strategies for BMT-related to pharmacy-driven multi-center research collaborations and clinician burnout
- Explain allogeneic chimeric antigen receptor T-cells (CAR-T) therapies
- Compare blinatumomab versus CD19 Chimeric Antigen Receptor T-cells (CAR-T) therapy for ALL
- Evaluate the current CAR-T landscape for DLBCL across varied institution and practice

2022 Tandem Pharmacist Conference Program Planning Committee

FIRST NAME	LAST NAME	CREDENTIALS	AFFILIATION	EMAIL	ROLE
Rebecca	Gonzalez	PharmD, BCOP	Moffitt Cancer Center	rebecca.gonzalez@moffitt.org	Chair

Breana	Goscicki	PharmD, BCPPS	UPMC Childrens Hospital	goscickib@upmc.edu	Chair Elect
Telyssa	Anderson	PharmD, BCOP, MBA	MD Anderson Cancer Center	taanderson@mdanderson.org	Member
David	Eplin	PharmD, BCOP	US Department of Veterans Affairs	dwright.eplin@va.gov	Member
Craig	Freyer	PharmD, BCOP	Hospital of the University of Pennsylvania	craig.freyer@gmail.com; craig.freyer@uphs.upenn.edu	Member
Tatjana	Grgic	PharmD, BCOP, CPP	University of North Carolina	tatjana.grgic@unchealth.unc.edu	Member
Alison	Gulbis	PharmD, BCOP	MD Anderson Cancer Center	alison.gulbis@gmail.com	Member
Kelsey	Konrardy	PharmD	University of Kansas Health System	kkonrardy@kumc.edu	Member
Chelsea	Minor	PharmD, BCPS, BCOP	Washington University School of Medicine	chelsea.minor@wustl.edu	Member
Sarah	Perreault	PharmD, BCPS, BCOP	Yale New Haven Hospital	SeraPerreault@gmail.com; sarah.perreault@ynhh.org	Member
Terri Lynn	Shigle	PharmD, BCOP	MD Anderson Cancer Center	TShigle@mdanderson.org	Member, Steering Committee Liaison
Meg	Taylor	PharmD	MJH Life Sciences/ Pharmacy Times CE	megcroom@gmail.com	Member
Teresa	Thakrar	PharmD, BCOP	Indiana University Health	teresackam@gmail.com	Member

**Activity Agenda & Faculty
2022 Tandem Pharmacists Conference Schedule**

Time	Presentation	Speaker	UAN Number	CE
	Day 1 (total = 7 CE)			
8:30- 8:45	Welcome/Overview 2022 Tandem Pharmacist Conference	Rebecca Gonzalez, PharmD, BCOP		
8:45-9:30	Infection prevention and management in CAR T patients	Josh Hill, MD	0391-9999-22-001-L01-P	0.75
9:30-10:00	Pharmacy SIG Update	Colleen Timlin, PharmD, BCOP	0391-9999-22-002-L01-P	0.5
10:00-10:15	Morning Break			

10:15-11:00	Allogeneic Chimeric Antigen Receptor T-cells (CAR-T) Primer	Sarah Schmidt, PharmD, BCOP	0391-9999-22-003-L01-P	0.75
11:00-12:00	COVID-19: Vaccination and Monoclonal Therapy Strategies in HCT/CI Patients	Yanina Pasikhova, PharmD, BCPS AQ-ID, BCIDP	0391-9999-22-004-L01-P	1
12:00-1:15	Lunch Break			
1:15-1:45	Pharmacy-Driven Multi-Center Research: Tips for Conducting and Managing Research Collaborations	Janel Long-Boyle, PharmD, PhD	0391-9999-22-005-L01-P	0.5
1:45-2:30	Updates from the American Society of Hematology Annual Meeting 2021: Part I	Shawn Griffin PharmD, BCOP	0391-9999-22-006-L01-P	0.75
2:30-2:45	Afternoon Break			
2:45-3:30	Updates from the American Society of Hematology Annual Meeting 2021: Part 2	Jamie Ziggas, PharmD, BCOP	0391-9999-22-007-L01-P	0.75
3:30-4:00	Bone Health and Vitamin D - Role in HCT Patients	Savannah Gulley, PharmD, BCPPS	0391-9999-22-008-L01-P	0.5
4:00-4:15	Afternoon Break			
4:15 – 4:30	Pharmacy NIA Grant Update and Best Abstracts: Acquired Immunity in Patients with Multiple Myeloma Undergoing Maintenance Therapy post-Autologous Stem Cell Transplantation	Dragos Plesca, PhD, PharmD, BCOP, DPLA	0391-9999-22-009-L01-P	1.5
4:30 – 4:45	Pharmacy NIA Grant Update and Best Abstracts: Implementation of Preemptive Pharmacogenomics Testing in Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy Patients	Susie Long, PharmD	0391-9999-22-010-L01-P	
4:45 – 5:00	Pharmacy NIA Grant Update and Best Abstracts: Safety and Efficacy of Prophylactic Levofloxacin in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients	Julia Gardner, PharmD	0391-9999-22-011-L01-P	
5:00 – 5:15	Pharmacy NIA Grant Update and Best Abstracts: Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)	Izabela Mazur, PharmD	0391-9999-22-012-L01-P	

5:15 – 5:30	Pharmacy NIA Grant Update and Best Abstracts: Baseline Hemoglobin Affects Outcomes after Melphalan-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation	Tate Feeney, PharmD	0391-9999-22-013-L01-P	
5:45-7:00	Pharmacy Reception and Awards Presentation			
	Day 2 (total = 6.75 CE)			
8:30-8:45	Welcome/Overview 2022 Tandem Pharmacist Conference	Breana Gosicki, PharmD, BCPPS		
8:45-9:15	Challenging Case: Primary Graft Failure	Lauren Ice, PharmD, BCOP	0391-9999-22-014-L01-P	0.5
9:15-10:15	HCT for Inherited Bone Marrow Failures in Pediatrics	Binni Kunvarjee, PharmD, BCOP	0391-9999-22-015-L01-P	1
10:15-10:30	Morning Break			
10:30-11:15	Updates in GVHD: New therapies for Prevention and Treatment	Arpita Gandhi, PharmD, BCOP	0391-9999-22-016-L01-P	0.75
11:15-12:00	Being WELL in clinician well-being	Amy Pick, PharmD, BCOP	0391-9999-22-017-L01-P	0.75
12:00-1:15	Lunch Break (Roundtable discussions: Conditioning + GVHD ppx, IEC, reimbursement/drug acquisition, pediatrics, aGVHD, new practitioner/precepting			
1:15- 2:15	New Drug Updates for Multiple Myeloma	Ryan Miller, PharmD, BCOP	0391-9999-22-018-L01-P	1
2:15-2:30	Afternoon Break			
2:30-3:00	HHV6 - Challenging Case set-up	Amanda Al-Bahou, PharmD	0391-9999-22-019-L01-P	0.5
3:00-4:00	CD19 Directed Therapy Debate: Blinatumomab vs. CD19 Chimeric Antigen Receptor T-cells (CAR-T) for ALL	Bernard “Bernie” Lawrence Marini, PharmD, BCOP & Anthony J. Perissinotti, PharmD, BCOP	0391-9999-22-020-L01-P	1
4:00-4:15	Afternoon Break			

4:15-5:30	Navigating the current CAR-T landscape for DLBCL: Best Practice Panel Perspectives	Speakers: 1. David Eplin, PharmD, BCOP 2. Craig Freyer, PharmD, BCOP 3. Jennifer Collins, PharmD 4. Zahra Mahmoudjafari, PharmD, BCOP	0391-9999-22-021-L01-P	1.25
-----------	--	---	------------------------	------



Accreditation - Pharmacists

The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award up to 13.75 CEUs to pharmacists who complete the activity and evaluation forms. There are both knowledge-based and application-based sessions in this activity. Please see the agenda above for a listing of the ACPE Universal Activity Numbers (UANs) associated with each session.

Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the live activity. **Please submit all evaluations and credit requests no later than May 24, 2022 to ensure your credit fulfillment. CE credit cannot be awarded past 60 days from the activity date.**

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CE information.
3. Participate in the CE activity.
4. Complete the CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
5. If you are requesting ACPE pharmacy credit—your CE credits will be submitted electronically to the CPE Monitor.

Disclosure Policy

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

The individuals listed in the table below report the following relevant disclosures.

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Alison Gulbis, PharmD, BCOP	Planning Committee	1. EUSA Pharma	1. Advisory Board	Relationship ended in January 2021
Amanda Al-Bahou, PharmD	Faculty	No relevant financial relationships	NA	NA
Amanda Seddon, PharmD, BCPS, BCOP	Faculty	1. Omeros	1. Non-CE Consulting	Relationship ended in March 2021.
Amy Pick, PharmD, BCOP	Faculty	No relevant financial relationships	NA	NA
Anthony J. Perissinotti, PharmD, BCOP	Faculty	No relevant financial relationships	NA	NA
Arpita Gandhi, PharmD, BCOP	Faculty	No relevant financial relationships	NA	NA
Ashley Teusink-Cross, PharmD	Faculty	1. Mesoblast 2. Jazz Pharmaceuticals	1. Non-CE Consulting 2. Non- CE Speakers Bureau	Relationship with Mesoblast ended in 2020. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Bernard Marini, PharmD, BCOP	Faculty	No relevant financial relationships	NA	NA
Binni Kunvarjee, PharmD	Faculty	No relevant financial relationships	NA	NA
Breana Goscicki, PharmD, BCPPS	Planning Committee Chair Elect	No relevant financial relationships	NA	NA
Chelsea Minor, PharmD, BCPS, BCOP	Planning Committee	No relevant financial relationships	NA	NA
Colleen Timlin, PharmD, BCOP	Faculty	No relevant financial relationships	NA	NA
Craig W. Freyer, PharmD, BCOP	Planning Committee, Faculty	1. Astellas, Incyte, EUSA Pharma, Servier 2. Astellas	1. Non-CE Consulting	Non-CE Consulting relationships ended in 2020. All final planning decisions concerning content, learning

		3. Bluebird Bio, Janssen	2.Non-CE Speakers Bureau 3: Other (Stock Ownership)	objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Dragos C. Plesca, PharmD, PhD, BCOP, DPLA	Faculty	1. Coherus, Heron, Permier, Merck, EUSA Pharman, Mylan Pharmaceuticals, Genzyme	1.Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Dwight “David” Eplin, II, PharmD, BCOP	Planning Committee	No relevant financial relationships	NA	NA
Heather Tarbox, MPH	TFF Staff	No relevant financial relationships	NA	NA
Izabela Mazur, PharmD	Faculty	No relevant financial relationships	NA	NA
Jamie Ziggas, PharmD	Faculty	1. Seagen	1. Advisory Board	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Janel Long-Boyle, PharmD, PhD	Faculty	1.Jasper Therapeutics, Trellis Bioscience, Omeros 2. InsightRX	1. Non-CE Consulting 2.Scientific Advisor	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Jas Chahal, PhD	TFF Staff	No relevant financial relationships	NA	NA
Jennifer Collins, PharmD, BCOP	Faculty	No relevant financial relationships	NA	NA
Jessica Scott	ASTCT Staff	No relevant financial relationships	NA	NA
Joshua A. Hill, MD	Faculty	1. Allogene, Allovir, Amplyx, Covance/CSLBehring, Gilead, Takeda,	1.Non –CE Consulting	Relationship with Gilead ended in 2019, Takeda and CRISPR ended in 2020, and Allogene,

		CRISPR, Octapharma AG, OptumHealth 2. Allovir, Golead, Karius, Deverra	2. Contract Research	Octapharma AG, and OptumHealth ended in 2021. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Julia Gardner, PharmD	Faculty	No relevant financial relationships	NA	NA
Kelsey Konrardy, PharmD	Planning Committee	No relevant financial relationships	NA	NA
Lauren Ice, Pharm D, BCOP, BCPS	Faculty	1. WoltersKluwer	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Margaret Taylor, PharmD, BCPS	Planning Committee	No relevant financial relationships	NA	NA
Rebecca Gonzalez, PharmD, BCOP	Planning Committee Chair	No relevant financial relationships	NA	NA
Ryan Miller, PharmD, BCOP	Faculty	No relevant financial relationships	NA	NA
Sarah Perreault, PharmD, BCPS, BCOP	Planning Committee	No relevant financial relationships	NA	NA
Sarah Schmidt, PharmD, BCOP	Faculty	1. Kayropharm and BMS	1. Advisory Board	Relationships ended in 2021.
Savannah Gulley, PharmD, BCPPS	Faculty	No relevant financial relationships	NA	NA
Shawn Griffin, PharmD	Faculty	No relevant financial relationships	NA	NA
Susie Long, PharmD	Faculty	No relevant financial relationships	NA	NA
Tate Feeney, Pharm D	Faculty	No relevant financial relationships	NA	NA
Tatjana Grgic, PharmD, BCOP, CPP	Planning Committee	No relevant financial relationships	NA	NA
Telyssa Anderson,	Planning Committee	No relevant financial relationships	NA	NA

PharmD, MBA, BCOP				
Teresa Thakrar, PharmD, BCOP	Planning Committee	No relevant financial relationships	NA	NA
Terri Lynn Shigle, PharmD, BCOP	Planning Committee	1. Takeda 2. Takeda	1. Non-CE Consulting 2. Advisory Board	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Yanina Pasikhova, PharmD, BCPS AQ-ID, BCIDP	Faculty	No relevant financial relationships	NA	NA
Zahra Mahmoudjafari, PharmD, BCOP	Faculty	1. Celgene/GSK, Incyte, Omeros, BMD, Merck, Medexus, Coherus	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.

Disclosure of Unlabeled Use

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment

This activity is supported by an educational grants from Jazz Pharmaceuticals.

Disclaimer

The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.